{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:33:24Z","timestamp":1761802404052,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.canep.2021.101929","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T06:55:06Z","timestamp":1617346506000},"page":"101929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-7236","authenticated-orcid":false,"given":"Lucie","family":"Pehalova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Krejci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Halamkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-326X","authenticated-orcid":false,"given":"Lenka","family":"Smardova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Snajdrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladislav","family":"Dusek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdw604","article-title":"Causes of death among cancer patients","volume":"28","author":"Zaorsky","year":"2017","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.canep.2021.101929_bib0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canep.2021.101929_bib0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1476-5381.2010.01100.x","article-title":"Therapy-related myeloid neoplasms: pathobiology and clinical characteristics","volume":"162","author":"Sill","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.canep.2021.101929_bib0025","first-page":"1378","article-title":"Carcinogenic potential of antitumor therapies \u2013 is the risk predictable?","volume":"22","author":"Nenova","year":"2017","journal-title":"J BUON"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7147","article-title":"Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France","volume":"2","author":"Jabagi","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-006-9460-0","article-title":"Leukemia following breast cancer: an international population-based study of 376,825 women","volume":"105","author":"Howard","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdn530","article-title":"Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers","volume":"20","author":"Beadle","year":"2009","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.canep.2021.101929_bib0045","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canep.2021.101929_bib0050","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1158\/1055-9965.EPI-08-0109","article-title":"Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan","volume":"17","author":"Lee","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0055","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","article-title":"Second malignancies after breast cancer: the impact of different treatment modalities","volume":"98","author":"Kirova","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0060","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.breast.2005.11.007","article-title":"Increased risk of acute myeloid leukaemia after treatment for breast cancer","volume":"15","author":"Renella","year":"2006","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0065","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.23212","article-title":"Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study","volume":"122","author":"Verkooijen","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjh.14530","article-title":"Subsequent malignancies among long-term survivors of hodgkin lymphoma and non-hodgkin lymphoma: a pooled analysis of German cancer registry data (1990\u20132012)","volume":"177","author":"Baras","year":"2017","journal-title":"Br J Haematol."},{"issue":"4","key":"10.1016\/j.canep.2021.101929_bib0075","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ijc.25706","article-title":"Risk of second cancer after lymphohematopoietic neoplasm","volume":"129","author":"Royle","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.canep.2021.101929_bib0080","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","article-title":"Second primary cancers among 109 000 cases of non-hodgkin\u2019s lymphoma","volume":"93","author":"Brennan","year":"2005","journal-title":"Br. J. Cancer"},{"year":"2021","series-title":"International Rules for Multiple Primary Cancers (ICD-0 Third Edition)","author":"IACR","key":"10.1016\/j.canep.2021.101929_bib0090"},{"year":"2021","series-title":"Czech National Cancer Registry","author":"Institute of Health Information","key":"10.1016\/j.canep.2021.101929_bib0095"},{"year":"2021","series-title":"Demographic Yearbook of the Czech Republic - 2017","author":"Czech statistical office","key":"10.1016\/j.canep.2021.101929_bib0100"},{"year":"2021","series-title":"Death Certificate System","author":"Institute of Health Information","key":"10.1016\/j.canep.2021.101929_bib0105"},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"year":"2013","series-title":"Revision of the European Standard Population: Report of Eurostat\u2019s Task Force: 2013 Edition","author":"Pace","key":"10.1016\/j.canep.2021.101929_bib0115"},{"year":"1988","series-title":"Applied Regression Analysis and Other Multivariable Methods","author":"Kleinbaum","key":"10.1016\/j.canep.2021.101929_bib0120"},{"issue":"4 Suppl","key":"10.1016\/j.canep.2021.101929_bib0125","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/1097-0142(197710)40:4+<1892::AID-CNCR2820400820>3.0.CO;2-H","article-title":"Statistical methods for studying multiple primary malignant neoplasms","volume":"40","author":"Schoenberg","year":"1977","journal-title":"Cancer"},{"issue":"82","key":"10.1016\/j.canep.2021.101929_bib0130","first-page":"1","article-title":"Statistical methods in cancer research. Volume II - the design and analysis of cohort studies","volume":"1","author":"Breslow","year":"1987","journal-title":"IARC Sci. Publ."},{"year":"2019","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","key":"10.1016\/j.canep.2021.101929_bib0135"},{"year":"2017","series-title":"IBM SPSS Statistics for Windows, Version 25.0","author":"IBM Corp. Released","key":"10.1016\/j.canep.2021.101929_bib0140"},{"year":"2021","series-title":"Joinpoint Regression Program \u2013 Surveillance Research Program","key":"10.1016\/j.canep.2021.101929_bib0145"},{"issue":"6993","key":"10.1016\/j.canep.2021.101929_bib0150","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/bmj.310.6993.1491","article-title":"Evidence of an association between non-hodgkin\u2019s lymphoma and skin cancer","volume":"310","author":"Adami","year":"1995","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00042728-200501000-00014","article-title":"Skin cancer and non-hodgkin\"s lymphoma: examining the link","volume":"31","author":"Hu","year":"2005","journal-title":"Dermatol. Surg."},{"issue":"7","key":"10.1016\/j.canep.2021.101929_bib0160","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E","article-title":"Second cancers following non-hodgkin\u2019s lymphoma","volume":"67","author":"Travis","year":"1991","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.canep.2021.101929_bib0165","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","article-title":"Second primary neoplasms following non-hodgkin\u2019s lymphoma in New South Wales, Australia","volume":"82","author":"Brennan","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.canep.2021.101929_bib0170","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/bjc.1996.642","article-title":"Non-hodgkin\u2019s lymphomas, chronic lymphocytic leukaemias and skin cancers","volume":"74","author":"Levi","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jnci\/dji022","article-title":"Ultraviolet radiation exposure and risk of malignant lymphomas","volume":"97","author":"Smedby","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0180","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1055-9965.EPI-06-1068","article-title":"Sun exposure and non-hodgkin lymphoma","volume":"16","author":"Armstrong","year":"2007","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"20","key":"10.1016\/j.canep.2021.101929_bib0185","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2013-04-497586","article-title":"Exposure to UV radiation and risk of hodgkin lymphoma: a pooled analysis","volume":"122","author":"Monnereau","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canep.2021.101929_bib0190","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2008.005157","article-title":"Therapy-related myeloid neoplasms","volume":"94","author":"Larson","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.canep.2021.101929_bib0195","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.canep.2021.101929_bib0200","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2011-03-342485","article-title":"Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US intergroup study E2997","volume":"118","author":"Smith","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0205","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-hodgkin\u2019s lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clml.2013.10.013","article-title":"Acute myeloid leukemia following myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis","volume":"14","author":"Jabbour","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0215","first-page":"1","article-title":"An unlikely Rapid transformation of myelodysplastic syndrome to acute leukemia: a case report","volume":"21","author":"Pourmoussa","year":"2017","journal-title":"Perm J"},{"issue":"11","key":"10.1016\/j.canep.2021.101929_bib0220","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdf289","article-title":"Long-term risk of second malignancy after treatment of hodgkin\u2019s disease: the influence of treatment, age and follow-up time","volume":"13","author":"Abrahamsen","year":"2002","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.canep.2021.101929_bib0225","first-page":"75","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.22672","article-title":"Risk of second cancer after chronic lymphocytic leukemia","volume":"121","author":"Sch\u00f6llkopf","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2021.101929_bib0235","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4342","article-title":"An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States","volume":"6","author":"Kumar","year":"2018","journal-title":"Peer J"},{"issue":"6","key":"10.1016\/j.canep.2021.101929_bib0240","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.canep.2021.101929_bib0245","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1080\/10428190600880977","article-title":"Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy","volume":"47","author":"Callea","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0250","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.biopha.2011.04.006","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide","volume":"65","author":"Colovi\u0107","year":"2011","journal-title":"Biomed. Pharmacother."},{"issue":"18","key":"10.1016\/j.canep.2021.101929_bib0255","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","article-title":"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"25","author":"Zhou","year":"2012","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-3329-2-1","article-title":"The International sarcoma kindred study consortium. An increased incidence of hodgkin\u2019s lymphoma in patients with adult-onset sarcoma","volume":"2","author":"Downing","year":"2012","journal-title":"Clin. Sarcoma Res"},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0270","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.bjc.6603589","article-title":"Mortality and incidence of second cancers following treatment for testicular cancer","volume":"96","author":"Robinson","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"38","key":"10.1016\/j.canep.2021.101929_bib0275","doi-asserted-by":"crossref","first-page":"e1626","DOI":"10.1097\/MD.0000000000001626","article-title":"Secondary primary malignancy risk in patients with ovarian cancer in Taiwan: a nationwide population-based study","volume":"94","author":"Hung","year":"2015","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.canep.2021.101929_bib0280","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1464-410X.2006.06004.x","article-title":"Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study","volume":"97","author":"Beisland","year":"2006","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.canep.2021.101929_bib0285","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4143\/crt.2016.543","article-title":"Second primary cancer risk among kidney cancer patients in Korea: a population-based cohort study","volume":"50","author":"Joung","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.canep.2021.101929_bib0290","first-page":"865","article-title":"Second cancers after medulloblastoma: population-based results from the United States and Sweden","volume":"8","author":"Goldstein","year":"1997","journal-title":"Cancer Causes Control."},{"issue":"5","key":"10.1016\/j.canep.2021.101929_bib0295","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1210\/jc.2005-2009","article-title":"Second primary cancers in thyroid cancer patients: a multinational record linkage study","volume":"91","author":"Sandeep","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.canep.2021.101929_bib0300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cam4.1266","article-title":"Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes","volume":"7","author":"Swaika","year":"2018","journal-title":"Cancer Med"},{"issue":"25","key":"10.1016\/j.canep.2021.101929_bib0305","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/bloodadvances.2017007930","article-title":"The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study","volume":"1","author":"Jonsdottir","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.canep.2021.101929_bib0310","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with hodgkin\u2019s lymphoma treated during adulthood","volume":"107","author":"Matasar","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.canep.2021.101929_bib0315","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:28:42Z","timestamp":1761802122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782121000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":63,"alternative-id":["S1877782121000461"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2021.101929","relation":{},"ISSN":["1877-7821"],"issn-type":[{"type":"print","value":"1877-7821"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2021.101929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101929"}}